HCP
RPRX icon

Hexagon Capital Partners’s Royalty Pharma RPRX Stock Holding History

Hexagon Capital Partners’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-715
Closed -$22.3K – 1364
2025
Q1 		$22.3K Buy
715
+1
+0.1% +$32 ﹤0.01% 720
2024
Q4 		$18.2K Buy
714
+365
+105% +$9.68K ﹤0.01% 818
2024
Q3 		$9.87K Buy
349
+13
+4% +$360 ﹤0.01% 929
2024
Q2 		$8.86K Sell
336
-108
-24% -$2.99K ﹤0.01% 903
2024
Q1 		$13.5K Sell
444
-105
-19% -$3.1K ﹤0.01% 776
2023
Q4 		$15.4K Sell
549
-69
-11% -$1.9K ﹤0.01% 722
2023
Q3 		$16.8K Buy
+618
New +$18.4K ﹤0.01% 610
2022
Q4 		– Sell
-9
Closed – – 1504
2022
Q3 		$0 Buy
+9
New +$384 ﹤0.01% 1413

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CIA
Caledonia Investments (Australia) Sydney NSW, Australia $2.93B AUM 37.21% 1-Year Est. Return

Hexagon Capital Partners's RPRX Position: Q2 2025 in Review

Hexagon Capital Partners sold out of Royalty Pharma (RPRX) in Q2 2025, closing a stake of 715 shares — an estimated $22.3K sold.

Hexagon Capital Partners first reported a position in RPRX in Q3 2022 and held it in 8 quarters. The position peaked at $22.3K in Q1 2025. 454 funds tracked by Wall St. Rank hold RPRX as of Q2 2025.

  • Hexagon Capital Partners reported no remaining Royalty Pharma position as of Q2 2025 after selling out during the quarter.
  • Hexagon Capital Partners sold 715 Royalty Pharma shares in Q2 2025, an estimated $22.3K.
  • Hexagon Capital Partners first reported a position in Royalty Pharma in Q3 2022 and held it in 8 quarters.
  • Hexagon Capital Partners's Royalty Pharma position peaked at $22.3K in Q1 2025.
  • 454 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2025.

Based on Hexagon Capital Partners's 13F filing for Q2 2025, filed 11 Aug 2025.